Main Menu

News and features 

Read the latest stories about our world-leading research, science, fundraising and philanthropy. 

To find out more, you can contact our media team, follow us on social media or visit our press release archive.


Sign up for our newsletters


News

Cancer cells pretend to be ‘super fit’ to outsmart normal cells and invade the body 23
Jul
2024

Scientists have discovered that some cancer cells pretend to be ‘super fit’ to fool normal healthy cells into giving them their nutrients, allowing them to expand and spread around the body. Find out more

MHRA approves first-in-class breast cancer drug 17
Jul
2024

The Institute of Cancer Research, London, welcomes the news that a new targeted breast cancer drug, capivasertib, has been approved by the Medicines & Healthcare products Regulatory Agency (MHRA) for treating the most common type of advanced breast cancer. Find out more

More men with advanced prostate cancer could be successfully treated with precision drug olaparib 15
Jul
2024

Scientists have discovered a genetic aberration found in some prostate cancers that could allow more men to be successfully treated with targeted drug olaparib Find out more

See all news articles

Features

Scientific achievements of 2023 05
Dec
2023

We've selected a range of discoveries from the academic year that highlight the quality and breadth of our basic, translational and clinical research. Find out more

Untapping the full potential of immunotherapies for more people with cancer 06
Jun
2023

Immunotherapy works by sparking the body’s own immune system into action against tumours. It has become a first-choice treatment for some types of cancer, and now there are exciting opportunities to unlock its benefits for more patients through research. Jane Shepley explores the story behind immunotherapy and how we can untap its potential. Find out more

Over a decade of abiraterone: the drug that revolutionised advanced prostate cancer care 14
Mar
2023

This Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer. We share the story of the drug’s discovery, how a landmark trial changed the way advanced prostate cancer is treated today, and what the drug has meant for patients who are currently treated with it. Find out more

See all feature articles